Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

15 total trials 11 completed

Trial Pipeline

ACTIVE NOT RECRUITING Phase 2

Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection

NCT05753215

ACTIVE NOT RECRUITING NA

Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men

NCT04175678

ACTIVE NOT RECRUITING Early Phase 1

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

NCT04037605

ACTIVE NOT RECRUITING Phase 1

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

NCT03153319

COMPLETED NA

Effect of Inorganic Nitrate Supplement on Blood Pressure

NCT03909789

COMPLETED NA

Time Limited Trials to Reduce Non-Beneficial Intensive Care Unit Treatments

NCT04181294

COMPLETED Phase 4

Comparison of Two Application Techniques for LET Gel

NCT04203225

COMPLETED Phase 4

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

NCT02845752

COMPLETED

Safety of Nitroglycerin for Field Treatment of STEMI

NCT02407002

COMPLETED Phase 1

Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men

NCT01382069

COMPLETED Phase 1

Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates

NCT01404247

COMPLETED Phase 4

Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

NCT01268553

COMPLETED Phase 3

Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)

NCT00860847

COMPLETED Phase 4

Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section

NCT00733278

COMPLETED

The Significance of Funguria in Hospitalized Patients

NCT00787085

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1
Phase 3 1
Phase 4 4

What the Pipeline for Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Shows

According to the ClinicalTrials.gov registry, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is linked to 15 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 11 are already marked complete, representing roughly 73% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center reports 5 late-stage studies (Phase 3 and Phase 4 combined) and 5 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is LET with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial